This is an overview of the best biotech stocks to buy in 2018 based off analysts ratings, research, fundamentals, and price history. In no way does this list cover all of the biotech stocks, but it highlights some of the top biotech stocks that should be on every trader’s radar.
Summary of best biotech stocks|
Best Biotech Stocks to Buy |
||
|---|---|---|
| Company | Ticker Symbol | Market Cap |
| Zafgen Inc. | ZFGN | $300M |
| Foundation Medicine Inc. | FMI | $5B |
| Heron Therapeutics Inc. | HRTX | $3B |
| Xenon Pharmaceuticals Inc. | XENE | $180M |
| Intellia Therapeutics Inc. | NTLA | $1.3B |
| Cara Therapeutics Inc. | CARA | $675M |
| Spark Therapeutics Inc. | ONCE | $3.4B |
| Albireo Pharma Inc. | ALBO | $445M |
| Ironwood Pharmaceuticals Inc. | IRWD | $3B |
| FibroGen Inc | FGEN | $5.4B |
| OPKO Health Inc | OPK | $2.9B |
Best Biotech Stocks to Buy 2018
Zafgen Inc. (ZFGN)
Zafgen is focused on improving the overall health and well-being of patients with severe obesity and other metabolic issues. This might sound strange, but given that obesity is actually an epidemic in the United States, Zafgen certainly has a place in the market going forward.
Foundation Medicine Inc. (FMI)
A molecular information company, FMI sells products based on it’s molecular technology to physicians and biopharmaceutical companies. There could be an increased demand for DMI’s services in the future, because their main product is used to analyze specimens of different types of cancer.
Heron Therapeutics Inc. (HRTX)
Similar to FMI, HRTX develops pharma products to treat cancer and chronic pain disorders. The company’s products include SUSTOL, which is designed to prevent nauseas and vomiting after receiving chemotherapy.
Xenon Pharmaceuticals Inc. (XENE)
A smaller biotech stock, Xenon is based in Canada and discovers and develops of therapeutic treatments for complex diseases like lipoprotein lipase deficiency. Evidently, Wall Street loves whatever XENE is doing, because the stock has tripled since the start of 2018.
Intellia Therapeutics Inc. (NTLA)
Although Intellia didn’t generate any profit as of September 2016, genome editing companies, which is what Intellia is, have been on quite the upwards trend. NTLA is up more than 30% for 2018.
Cara Therapeutics Inc. (CARA)
Cara is another pain management biotech stock. The company focuses on kappa opioid receptors to target the body’s peripheral nervous system. In just the past two months, as of the time of this post, CARA has doubled in value.
Spark Therapeutics Inc. (ONCE)
Creidit Suisse currently rates Spark Therapeutics as outperform, partially due to the companies promising pipeline of orphan disease drugs. Spark aims to treat multiple blinding diseases, hemophiliac diseases, and hematologic disorders.
What are Biotech Stocks?
Not to be confused with pharmaceutical stocks, biotech stocks are companies, often unprofitable ones, that research, create, and market drugs and healthcare equipment based off biology.
Live enzymes, bacteria, and other living organisms are often the foundation for biotech breakthroughs and research.
Pharmaceutical stocks typically do the same thing as biotech stocks, except pharma is based off of chemical compounds. Pharma companies use chemical compounds, like sodium bicarbonate diphosphate, for example, to create new treatments for ailments.
Ally Invest is the best online discount broker to trade biotech stocks for 2018.
With this offer, it’s possible to buy biotech stocks commission free for 90 days: Up to $3,500 cash bonus + commission free trades for new accounts. Learn More
